NCT00714285View on ClinicalTrials.gov

Immunogenicity and Safety Study of a GSK Influenza Vaccine Candidate in Adults.

PHASE1CompletedINTERVENTIONAL
Enrollment

420

Participants

Timeline

Start Date

July 14, 2008

Primary Completion Date

January 28, 2009

Study Completion Date

January 28, 2009

Conditions
Influenza
Interventions
BIOLOGICAL

GSK Biologicals' quadrivalent influenza vaccine

Single intramuscular dose on Day 0.

BIOLOGICAL

GSK Biologicals' trivalent influenza vaccine

Single intramuscular dose on Day 0.

Trial Locations (1)

500 03

GSK Investigational Site, Hradec Králové

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY